UniQure said the U.S. Food and Drug Administration no longer agreed that clinical data for the Dutch company's gene therapy ...

By analyzing data from three clinical trials treating children with the brain tumor medulloblastoma, scientists at St. Jude ...

The shift to risk-based quality management (RBQM) in clinical trials offers market opportunities in proactive risk strategies, focusing on patient safety and data integrity. Emphasizing digital ...

The report identifies opportunities in optimizing Basal Cell Carcinoma clinical trials through strategic location selection, understanding enrollment trends, and evaluating trial success rates. It ...

Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to ...

Experts at the 2025 OCT DACH conference will dive into the potential of the European region amid a shifting clinical trial ...

Avisi Technologies has released positive 12-month clinical data on the VisiPlate Aqueous Shunt from the VITA Trial. The VITA ...

Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ― ...

First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory ...

In the Phase 2 LEDA clinical trial in PPP, SLK demonstrated clinically meaningful and statistically significant benefit. Patients treated with SLK ...

Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to pr ...

UniQure NV plunged Monday after the drug developer said US regulators deemed the clinical data for its experimental gene-therapy for Huntington’s disease as insufficient.